350 related articles for article (PubMed ID: 33196901)
21. Antiresorptive drug-related osteonecrosis of the jaws, literature review and 5 years of experience.
Bernardi S; Di Girolamo M; Necozione S; Continenza MA; Cutilli T
Musculoskelet Surg; 2019 Apr; 103(1):47-53. PubMed ID: 29948937
[TBL] [Abstract][Full Text] [Related]
22. Antiresorptive agent-related osteonecrosis of the jaw: Position Paper 2017 of the Japanese Allied Committee on Osteonecrosis of the Jaw.
; Yoneda T; Hagino H; Sugimoto T; Ohta H; Takahashi S; Soen S; Taguchi A; Nagata T; Urade M; Shibahara T; Toyosawa S
J Bone Miner Metab; 2017 Jan; 35(1):6-19. PubMed ID: 28035494
[TBL] [Abstract][Full Text] [Related]
23. Antiresorptive agent-related osteonecrosis of the jaw risk in cancer patients before bone-modifying agent therapy: A retrospective study of 511 patients.
Kanno C; Kojima M; Tezuka Y; Yaginuma S; Kanaya Y; Kaneko T
Bone; 2023 Dec; 177():116892. PubMed ID: 37689127
[TBL] [Abstract][Full Text] [Related]
24. Monitoring indices of bone inflammatory activity of the jaw using SPECT bone scintigraphy: a study of ARONJ patients.
Hata H; Kitao T; Sato J; Asaka T; Ohga N; Imamachi K; Hirata K; Shiga T; Yamazaki Y; Kitagawa Y
Sci Rep; 2020 Jul; 10(1):11385. PubMed ID: 32647190
[TBL] [Abstract][Full Text] [Related]
25. Incidence of antiresorptive agent-related osteonecrosis of the jaw: A multicenter retrospective epidemiological study in Hyogo Prefecture, Japan.
Nashi M; Kishimoto H; Kobayashi M; Tachibana A; Suematsu M; Fujiwara S; Ota Y; Hashitani S; Shibatsuji T; Nishida T; Fujimura K; Furudoi S; Ishida Y; Ishii S; Fujita T; Iwai S; Shigeta T; Harada T; Miyai D; Takeda D; Akashi M; Noguchi K; Takenobu T
J Dent Sci; 2023 Jul; 18(3):1156-1163. PubMed ID: 37404599
[TBL] [Abstract][Full Text] [Related]
26. Synchronous antiresorptive osteonecrosis of the jaws and breast cancer metastasis.
Flores IL; dos Santos-Silva AR; Della Coletta R; Vargas PA; Lopes MA
Oral Surg Oral Med Oral Pathol Oral Radiol; 2014 Mar; 117(3):e264-8. PubMed ID: 24528798
[TBL] [Abstract][Full Text] [Related]
27. Zoledronic acid promotes TLR-4-mediated M1 macrophage polarization in bisphosphonate-related osteonecrosis of the jaw.
Zhu W; Xu R; Du J; Fu Y; Li S; Zhang P; Liu L; Jiang H
FASEB J; 2019 Apr; 33(4):5208-5219. PubMed ID: 30624969
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapeutic and antiresorptive combination therapy suppressed lymphangiogenesis and induced osteonecrosis of the jaw-like lesions in mice.
Kuroshima S; Yamashita J
Bone; 2013 Sep; 56(1):101-9. PubMed ID: 23727433
[TBL] [Abstract][Full Text] [Related]
29. [Current situation and future issues of antiresorptive agent-related osteonecrosis of the jaw].
Takaoka K; Kishimoto H
Nihon Yakurigaku Zasshi; 2019; 153(1):22-27. PubMed ID: 30643088
[TBL] [Abstract][Full Text] [Related]
30. [A Case Report of Kampo Medicine Improving the Symptoms of Antiresorptive Agent-related Osteonecrosis of the Jaw (ARONJ)].
Yamazaki Y; Shimada M
Yakugaku Zasshi; 2021; 141(9):1123-1127. PubMed ID: 34471013
[TBL] [Abstract][Full Text] [Related]
31. Nonexposed antiresorptive agent-related osteomyelitis of the jaw: a single-center cohort study.
Watanabe T; Yoshida T; Akizuki S; Yamanaka S; Nakao K; Fukuhara S; Asai K; Uozumi R; Bessho K
J Bone Miner Metab; 2022 Jul; 40(4):657-662. PubMed ID: 35534635
[TBL] [Abstract][Full Text] [Related]
32. Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.
Ghidini G; Manfredi M; Giovannacci I; Mergoni G; Sarraj A; Mureddu M; Giunta G; Bonanini M; Meleti M; Vescovi P
Minerva Stomatol; 2017 Aug; 66(4):135-140. PubMed ID: 28497661
[TBL] [Abstract][Full Text] [Related]
33. Continuous Mandibular Nerve Block for Intractable Mandibular Pain Due to Antiresorptive Agent-Related Osteonecrosis of the Jaw: A Case Report.
Fujimoto D; Obata N; Motoyama Y; Sato H; Takao Y; Mizobuchi S
Kobe J Med Sci; 2020 Nov; 66(3):E90-E93. PubMed ID: 33431781
[TBL] [Abstract][Full Text] [Related]
34. Is the conservative non-surgical management of medication-related osteonecrosis of the jaw an appropriate treatment option for early stages? A long-term single-center cohort study.
Ristow O; Rückschloß T; Müller M; Berger M; Kargus S; Pautke C; Engel M; Hoffmann J; Freudlsperger C
J Craniomaxillofac Surg; 2019 Mar; 47(3):491-499. PubMed ID: 30642734
[TBL] [Abstract][Full Text] [Related]
35. Antiresorptive agent-related osteonecrosis of the jaw in osteoporosis patients from Asian countries.
Taguchi A; Shiraki M; Morrison A; Khan AA
Osteoporos Sarcopenia; 2017 Jun; 3(2):64-74. PubMed ID: 30775507
[TBL] [Abstract][Full Text] [Related]
36. Experience with the treatment of bisphosphonate-related osteonecrosis of the jaw.
Janovska Z; Mottl R; Slezak R
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2015 Jun; 159(2):313-7. PubMed ID: 24108250
[TBL] [Abstract][Full Text] [Related]
37. Antiresorptive Agents and Anti-Angiogenesis Drugs in the Development of Osteonecrosis of the Jaw.
Allegra A; Innao V; Pulvirenti N; Musolino C
Tohoku J Exp Med; 2019 May; 248(1):27-29. PubMed ID: 31080196
[TBL] [Abstract][Full Text] [Related]
38. Antiresorptive agents-related osteonecrosis of the jaw (ARONJ) in rheumatoid arthritis.
Fujieda Y; Atsumi T
J Bone Miner Metab; 2020 Sep; 38(5):739-741. PubMed ID: 32591907
[No Abstract] [Full Text] [Related]
39. [Use of a xenogeneic collagen matrix on extraction sockets: a new approach in ARONJ prevention (in german)].
Kuster I; Valdec S; Rücker M; Bichsel D
Swiss Dent J; 2020 Feb; 130(2):139-145. PubMed ID: 32031353
[TBL] [Abstract][Full Text] [Related]
40. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents.
Hauer L; Jambura J; Hrusak D; Chalupova M; Posta P; Rusnak S; Vyskocil V
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2020 Mar; 164(1):100-107. PubMed ID: 30647474
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
